These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10052896)

  • 1. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol.
    Abate G; Miörner H
    J Antimicrob Chemother; 1998 Dec; 42(6):735-40. PubMed ID: 10052896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
    Zhang D; Wang Y; Lu J; Pang Y
    Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
    Gonzalo X; Drobniewski F
    J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium kansasii to amoxycillin and ticarcillin in combination with clavulanic acid.
    Wong CS; Palmer GS; Cynamon MH
    J Antimicrob Chemother; 1988 Dec; 22(6):863-6. PubMed ID: 3149633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Segura C; Salvadó M; Collado I; Chaves J; Coira A
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1524-6. PubMed ID: 9624510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
    Dinçer I; Ergin A; Kocagöz T
    Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
    Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
    EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
    Al-Mutairi NM; Ahmad S; Mokaddas E
    Microb Drug Resist; 2018 Sep; 24(7):923-931. PubMed ID: 29336677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
    Antimicrob Agents Chemother; 2015; 59(6):3630-2. PubMed ID: 25824227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae.
    Cooper CE; Slocombe B; White AR
    J Antimicrob Chemother; 1990 Sep; 26(3):371-80. PubMed ID: 2121699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.
    Abate G; Hoffner SE
    Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.
    Jacobs MR; Spangler SK; Appelbaum PC
    J Antimicrob Chemother; 1990 Sep; 26(3):361-70. PubMed ID: 2228827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis.
    Cynamon MH; Palmer GS
    Antimicrob Agents Chemother; 1983 Sep; 24(3):429-31. PubMed ID: 6416162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
    Kurz SG; Wolff KA; Hazra S; Bethel CR; Hujer AM; Smith KM; Xu Y; Tremblay LW; Blanchard JS; Nguyen L; Bonomo RA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6085-96. PubMed ID: 24060876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic interaction of amoxycillin and clavulanic acid against 132 beta-lactamase positive Haemophilus isolates: a comparison with some other oral agents.
    Lapointe JR; Lavallée C
    J Antimicrob Chemother; 1987 Jan; 19(1):49-58. PubMed ID: 3494009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.
    Rey-Jurado E; Tudó G; de la Bellacasa JP; Espasa M; González-Martín J
    Int J Antimicrob Agents; 2013 Mar; 41(3):278-80. PubMed ID: 23312604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
    Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
    J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.